Nkarta
South San Francisco, California, United States · Biotechnology · 147 employees
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persis
Funding history
- Series at-the-market offering — $100.0M — Mar 2026
- Funding Round — $43.9M — Sep 2019
Recent signals
- Mar 26, 2026: Raised $100.0M in Series at-the-market offering
- Mar 25, 2026: SEC 8-K (8.01): On March 25, 2026, Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated for an at-the-market offering program. This program allows Nkarta to sell shares of its common stock valued at up to $100,000,000. The Company will control the sale parameters such as the number of shares and sale timings, along with conditions on pricing constraints. This strategic move is likely to enhance liquidity and may provide capital for future initiatives.
- Jun 06, 2025: Nkarta Appoints Shawn Rose as Chief Medical Officer and Head of R&D
- Dec 05, 2024: Launched Nkarta, Inc. announces IND clearance for investigator-sponsored trial of NKX019 targeting myasthenia gravis and the opening of enrollment for Ntrust-2.
- Jul 16, 2024: Nkarta Names Nadir Mahmood as President and David R. Shook, M.D., as Chief Medical Officer, Head of Research & Development
- Sep 06, 2019: Raised $43.9M
See plans & pricing → Track Nkarta’s funding, hiring, and signals — with verified contacts — on Fundz.